Therapy for non-clear cell histologies in renal cancer

Current Clinical Pharmacology

Volumn 6, Issue 3, 2011, Pages 169-180

  Bitting, Rhonda L ^a   Madden, John ^a   Armstrong, Andrew J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromophobe; Collecting duct carcinoma; mTOR inhibitors; Non clear cell papillary; Renal cell carcinoma; Targeted therapy; Translocation carcinoma; VEGFR inhibitors

Indexed keywords

AMG 208; ANTINEOPLASTIC AGENT; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; FORETINIB; GEMCITABINE; ISOTRETINOIN; IXABEPILONE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MK 2206; PAZOPANIB; PEMETREXED; PLACEBO; RECOMBINANT ALPHA INTERFERON; RILOTUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT; XL 184;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUBULE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052214958     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411797189460     Document Type: Review

References (100)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59(4): p. 225-49.
2. Chow WH et al. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281(17): p. 1628-31.
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8): p. 2530-40.
4. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J Clin Oncol 2009; 27(34): p. 5794-9.
5. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1): p. 133-41.
6. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28(5): p. 488-95.
7. Carroll PR, Murty VV, Reuter V, et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet 1987; 26(2): p. 253-9.
8. Kim WY, Kaelin WG. Kaelin Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22(24): p. 4991-5004.
9. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13(2 Pt 2): p. 680s-4.
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): p. 2271-81.
11. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295(21): p. 2516-24.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): p. 115-24.
13. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised placebo- controlled phase III trial. Lancet 2008; 372(9637): p. 449-56.
14. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28(6): p. 1061-8.
15. Rini BI. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): p. 5422-8.
16. Rini BI, Halabi S, Rosenberg JE, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): p. 3584-90.
17. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised double-blind phase III trial. Lancet 2007; 370(9605): p. 2103-11.
18. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): p. 125-34.
19. Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30(3): p. 220-7.
20. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183(2): p. 131-3.
21. Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94(1): p. 111-6.
22. Argani PM. Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005; 25(2): p. 363-78.
23. Truong LD. Shen SS. Shen Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 2011; 135(1): p. 92-109.
24. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23(12): p. 2763-71.
25. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26(3): p. 281-91.
26. Beck SD, Petal MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11(1): p. 71-7.
27. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25(11): p. 1316-22.
28. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28(2): p. 311-7.
29. Kwak C, Park YH, Jeong CW, et al. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 2007; 95(4): p. 317-23.
30. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167(1): p. 65-70.
31. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior prognosis and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17(2): p. 523-8.
32. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int 2009; 103(11): p. 1496-500.
33. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69(2): p. 230-5.
34. Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer 2006; 106(4): p. 783-8.
35. Advanced Bladder Cancer Overview Collaboration. Adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005; (2): CD005246.
36. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10(18 Pt 2): p. 6282S-9S.
37. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10(8): p. 757-63.
38. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26(2): p. 202-9;
39. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116(5): p. 1272-80.
40. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116(18): p. 4256-65.
41. Thoenes W, Störkel S, Rumpelt HJ, et al. Rumpelt Histopathology and classification of renal cell tumors (adenomas oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181(2): p. 125-43.
42. Delahunt B, Eble JN. Eble Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10(6): p. 537-44.
43. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005; 65(13): p. 5628-37.
44. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 2008; 112(7): p. 1480-8.
45. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto- oncogene in papillary renal carcinomas. Nat Genet 1997; 16(1): p. 68-73.
46. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18(14): p. 2343-50.
47. Fischer J, Palmedo G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998; 17(6): p. 733-9;
48. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993; 62: p. 89-124.
49. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73(1): p. 95-106.
50. Koski TA, Lehtonen HJ, Jee KJ, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer 2009; 48(7): p. 544-51.
51. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30(4): p. 406-10.
52. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67(7): p. 3171-6.
53. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26(1): p. 127-31.
54. Plimack E. Jonasch E. Bekele B. et al. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. In ASCO Genitourinary Cancers Symposium 2010.
55. Caglio S, Slimane K, May C, Escudier B. Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. J Clin Oncol 2010; 28(15s suppl; abstr TPS234)).
56. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16(13): p. 3507-16.
57. Srinivasan R, Linehan WM, Vaishampayan U, et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089) a dual MET/VEGRF2 inhibitor in patients with papillary renal carcinoma. J Clin Oncol 2009; 27(15s): p. abstr 5103.
58. Munshi N, Jeay S, Li Y, et al. ARQ 197 a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9(6): p.1544-53.
59. Mekhail T, Rich T, Rosen L, Semic-Suka Z, Savage RE, Senzer N. Final results: A dose escalation phase I study of ARQ 197 a selective c-Met inhibitor in patients with metastatic solid tumors. J Clin Oncol 2009; 27(15S): p. abstract 3548.
60. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281(36): p. 25903-14.
61. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009; 27(34): p. 5788-93.
62. A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer Clinicaltrials.gov identifier NCT01130519.
63. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1985; 48(3): p. 207-17.
64. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003; 22(6): p. 847-52.
65. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG. Immunohistochemical analysis of chromophobe renal cell carcinoma renal oncocytoma and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 2007; 131(8): p. 1290-7.
66. Akhtar M, Kardar H, Linjawi T, McClintock J, Ali MA Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Am J Surg Pathol 1995; 19(11): p. 1245-56.
67. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1 2 6 10 13 17 and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994; 145(2): p. 356-64.
68. Peyromaure M, Misrai V, Thiounn N, et al. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004. 100(7): p. 1406-10.
69. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996. 335(12): p. 865-75.
70. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977; 113(12): p. 1674-7.
71. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors lung wall defects and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2(2): p. 157-64.
72. Murakami T, Sano F, Huang Y, et al. Identification and characterization of Birt-Hogg-Dube associated renal carcinoma. J Pathol 2007; 211(5): p. 524-31.
73. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein FNIP1 and AMPK and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006; 103(42): p. 15552-7.
74. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation cell hyperproliferation and polycystic kidneys. J Natl Cancer Inst 2008; 100(2): p. 140-54.
75. Gad S, Lefèvre SH, Khoo SK, et al. Mutations in BHD and TP53 genes but not in HNF1beta gene in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 2007; 96(2): p. 36-40.
76. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003; 63(15): p. 4583-7.
77. Beckmann H, Su LK, Kadesch T. TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev 1990; 4(2): p. 167-79;
78. Hua X, Liu X, Ansari DO, Lodish HF. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 1998; 12(19): p. 3084-95.
79. Bajou K, Noël A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4(8): p. 923-8.
80. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. 2004 IARC Press: Lyon France.
81. Malouf GG, Camparo P, Molinié V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features biological behavior and prognostic factors. J Urol 2011; 185(1): p. 24-9.
82. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116(22): p. 5219-25.
83. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 2010; 34(9): p. 1295-303.
84. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011; 30(2): p. 127-38.
85. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007; 177(5): p. 1698-702.
86. Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 2004; 100(5): p. 976-85.
87. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995; 19(1): p. 1-11.
88. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(18): p. 3720-5.
89. Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24(9): p. e14.
90. Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106(1): p. 62-5.
91. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995; 55(3): p. 658-62.
92. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2010.
93. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98(12): p. 2566-75.
94. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27(2): p. 235-41.
95. Phase II Study of Afinitor vs. Sutent in patients with metastatic non-clear cell renal cell carcinoma (ASPEN) clinicaltrials.gov identifer NCT01108445.
96. Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib clinicaltrials.gov identifier NCT00979966.
97. RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (RAPTOR/ LFR08) clinicaltrials.gov identifier NCT00688753.
98. Armstrong AJ George DJ, Halabi S. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 2010; 28(15S; abstr 4631).
99. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7(1): p. 24-7.
100. Turnbull JD, Armstrong AJ, Morris K, et al. A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2010; 28S (abstr e15034).